Rapport Therapeutics (RAPP) Projected to Release Earnings on Thursday

Rapport Therapeutics (NASDAQ:RAPP) is expected to release its Q2 2026 results before the market opens on Thursday, August 6th. Analysts expect the company to announce earnings of ($0.93) per share and revenue of $20.00 million for the quarter. Interested persons are encouraged to explore the company’s upcoming Q2 2026 earning report page for the latest details on the call scheduled for Friday, August 7, 2026 at 9:30 AM ET.

Rapport Therapeutics (NASDAQ:RAPP) last announced its quarterly earnings data on Thursday, May 7th. The company reported ($0.42) earnings per share for the quarter, topping the consensus estimate of ($0.56) by $0.14. The company had revenue of $20.00 million for the quarter, compared to analysts’ expectations of $7.50 million. On average, analysts expect Rapport Therapeutics to post $-3 EPS for the current fiscal year and $-4 EPS for the next fiscal year.

Rapport Therapeutics Stock Performance

RAPP opened at $40.94 on Thursday. Rapport Therapeutics has a 1 year low of $13.62 and a 1 year high of $44.28. The company’s 50 day simple moving average is $39.16 and its 200 day simple moving average is $33.83. The stock has a market capitalization of $1.96 billion, a PE ratio of -15.75 and a beta of 0.94.

Insider Buying and Selling

In other news, major shareholder Rock Ventures V. L.P. Third sold 271,495 shares of the firm’s stock in a transaction on Thursday, May 7th. The shares were sold at an average price of $40.12, for a total value of $10,892,379.40. Following the transaction, the insider owned 6,437,733 shares of the company’s stock, valued at approximately $258,281,847.96. This trade represents a 4.05% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO Abraham Ceesay sold 2,210 shares of the firm’s stock in a transaction on Monday, July 27th. The shares were sold at an average price of $42.11, for a total transaction of $93,063.10. Following the completion of the transaction, the chief executive officer directly owned 537,607 shares in the company, valued at approximately $22,638,630.77. This represents a 0.41% decrease in their position. The SEC filing for this sale provides additional information. Over the last ninety days, insiders have sold 430,913 shares of company stock worth $17,308,315. 12.48% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in RAPP. Russell Investments Group Ltd. lifted its stake in shares of Rapport Therapeutics by 56.9% during the fourth quarter. Russell Investments Group Ltd. now owns 2,282 shares of the company’s stock worth $69,000 after purchasing an additional 828 shares in the last quarter. Meeder Asset Management Inc. purchased a new stake in shares of Rapport Therapeutics during the 4th quarter valued at about $37,000. Creative Planning raised its holdings in shares of Rapport Therapeutics by 12.8% during the 3rd quarter. Creative Planning now owns 11,959 shares of the company’s stock valued at $355,000 after buying an additional 1,357 shares during the period. Two Sigma Investments LP lifted its position in Rapport Therapeutics by 8.9% during the 3rd quarter. Two Sigma Investments LP now owns 21,500 shares of the company’s stock worth $639,000 after acquiring an additional 1,757 shares in the last quarter. Finally, Police & Firemen s Retirement System of New Jersey boosted its holdings in Rapport Therapeutics by 42.3% in the 4th quarter. Police & Firemen s Retirement System of New Jersey now owns 7,471 shares of the company’s stock worth $227,000 after acquiring an additional 2,219 shares during the period.

Analysts Set New Price Targets

A number of research firms have weighed in on RAPP. Leerink Partners initiated coverage on shares of Rapport Therapeutics in a research note on Wednesday, June 24th. They set an “outperform” rating and a $52.00 price target on the stock. Raymond James Financial began coverage on Rapport Therapeutics in a report on Friday, April 10th. They set a “strong-buy” rating and a $66.00 price objective for the company. William Blair started coverage on Rapport Therapeutics in a research report on Tuesday. They issued an “outperform” rating on the stock. Wall Street Zen raised Rapport Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, May 9th. Finally, BTIG Research reiterated a “buy” rating and issued a $65.00 target price on shares of Rapport Therapeutics in a report on Thursday, July 16th. One analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $57.86.

About Rapport Therapeutics

Rapport Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted therapies for patients with cancer. The company leverages a proprietary discovery engine to identify novel tumor-associated antigens and develop tailored biologic and small-molecule candidates designed to modulate key oncogenic pathways. With a pipeline comprising multiple preclinical and early clinical assets, Rapport is committed to advancing precision medicine approaches and addressing unmet needs in oncology.

Rapport’s discovery engine combines high-throughput screening, molecular profiling and in vivo validation to accelerate the progression of lead candidates from the laboratory to clinical evaluation.